From Medscape Psychiatry

Coverage from the

16th Clinical Trials on Alzheimer's Disease (CTAD) Conference

October 24 - 27, 2023; Boston, Massachusetts

October 24 - 27, 2023 Boston, Massachusetts
  • CTAD 2023 No Influence of APOE Status on Donanemab Efficacy New data from TRAILBLAZER-ALZ 2 show robust amyloid clearance with donanemab in APOE4 carriers and noncarriers, mitigating the risk of disease progression and dependency.
  • CTAD 2023 Novel Tau Blood Biomarker Shows Promise Plasma MTBR-tau243 reflects changes in tau pathology and can be used to stage AD tauopathy and to determine if cognitive symptoms are likely due to AD pathology.
  • CTAD 2023 Promising Phase 2 Results for Novel Oral Alzheimer's Drug An investigational dual PPAR agonist modifies Alzheimer's pathology and shows cognitive benefit in adults with mild-to-moderate disease and high plasma pTau-217 ratio, early data show.

Conference News

Medscape Psychiatry© 

Popular News From CTAD 2022

Previous Coverage

Related Resources